Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-03-03
2009-06-23
Vogel, Nancy (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S476000
Reexamination Certificate
active
07550295
ABSTRACT:
This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme.This invention provides a method of ligating duplex DNAs, a method of molecular cloning of DNA, a method of synthesizing polynucleotides, and a method of gene targeting.Lastly, this invention provides a recombinant DNA molecule composed of segments of DNA which have been joined ex vivo by the use of a sequence specific topoisomerase and which has the capacity to transform a suitable host cell comprising a DNA sequence encoding polypeptide activity.
REFERENCES:
patent: 4661450 (1987-04-01), Kempe et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5624826 (1997-04-01), Kato et al.
patent: 5766891 (1998-06-01), Shuman
patent: 6238884 (2001-05-01), Short et al.
patent: 6280977 (2001-08-01), Liang et al.
patent: 6291213 (2001-09-01), Rothstein et al.
patent: 6548277 (2003-04-01), Shuman
patent: 7026141 (2006-04-01), Shuman
patent: 0 373 914 (1994-07-01), None
patent: 0 625 572 (2001-04-01), None
patent: WO 85/04898 (1985-11-01), None
patent: WO 94/29443 (1994-12-01), None
patent: WO 96/19497 (1996-06-01), None
patent: WO 96/34981 (1996-11-01), None
patent: WO 97/24455 (1997-07-01), None
patent: WO 98/20122 (1998-05-01), None
patent: WO 98/55502 (1998-12-01), None
patent: WO 98/56943 (1998-12-01), None
patent: WO 00/12687 (2000-03-01), None
patent: WO 00/56878 (2000-09-01), None
patent: WO 01/62892 (2001-08-01), None
patent: WO 01/62943 (2001-08-01), None
patent: WO 02/16594 (2002-02-01), None
Arnott, et al., “DNA-RNA hybrid secondary structures,” J. Mol. Biol. 188(4) :631-640 (1986).
Carninci, et al., “High efficiency selection of full-length cDNA by improved biotinylated cap trapper,” DNA Research 4:61-66 (1997).
Carninci, et al., “ High efficiency full-length cDNA cloning by biotinylated CAP trapper,” Genomics 37(3) :327-36 (1996).
Cheng and Shuman, “A catalytic domain of eukaryotic DNA topoisomerase I,” J. Biol. Chem. 273(19) :11589-95 (1998).
Cheng and Shuman, “DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3′ mononucleotide overhang,” Nucleic Acids Res. 28(9) :1893-8 (2000).
Cheng and Shuman, “Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks,” Mol. Cell. Biol. 20(21) :8059-8068 (2000).
Cheng and Shuman, “Site-specific DNA transesterification by vaccinia topoisomerase: Role of specific phosphates and nucleosides,” Biochemistry 38(50) :16599-612 (1999).
Cheng, et al., “Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases,” Cell 92(6) :841-50 (1998).
Cheng, et al., “Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223 and Asn-228 as important for covalent catalysis,” J. Biol. Chem. 272(13) :8263-9 (1997).
Chong, S., et al., “Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element,” Gene 192(2) :271-281 (1997).
DiGate and Marians, “Molecular cloning and DNA sequence analysis ofEscherichia colitopoB, the gene encoding topoisomerase III,” J. Biol. Chem. 264(30) :17924-17930 (1989).
Edery, et al., “An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture),” Mol. Cell. Biol. 15(6) :3363-3371 (1995).
Ericsson, et al., “Characterization of ts16, a temperature-sensitive mutant of vaccinia virus,” J. Virol. 69(11) :7072-86 (1995).
Gross and Shuman, “Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription,” J. Virol. 70(12) :8549-5 (1996).
Haghighat and Sonenberg, “eIF4G dramatically enhances the binding of eIF4E to the mRNA 5′-cap structure,” J. Biol. Chem. 272(35) :21677-21680 (1997).
Haghighat, et al., “The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase,” J. Virol. 70:8444-8450 (1996).
Henningfeld and Hecht, “A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps,” Biochemistry 34(18) :6120-9 (1995).
Invitrogen Corporation, Carlsbad, California, catalog pp. 18, 29, 43, 44, 49-52 (1998).
Janknecht, et al., “Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus,” Proc. Natl. Acad. Sci. U.S.A. 88:8972-8976 (1991).
Kane and Shuman, “Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component,” J. Virol. 67(5) :2689-98 (1993).
Kato, et al., “Construction of a human full-length cDNA bank,” Gene 150:243-250 (1994).
Klemm, et al., “Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases,” J. Mol. Biol. 299(5) :1203-16 (2000).
Klemperer, et al., “Identification and characterization of the orf virus type I topoisomerase,” Virology 206:203-215 (1995).
Krogh and Shuman, “Catalytic mechanism of DNA topoisomerase IB,” Mol. Cell 5(6) :1035-41 (2000).
Krogh and Shuman, “DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate,” Biochemistry 39(21) :6422-32 (2000).
Krogh and Shuman, “Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site,” J. Biol. Chem. (2001).
Krogh, et al., “Effect of 2′-5′ phosphodiesters on DNA transesterification by vaccinia topoisomerase,” J. Biol. Chem. 276(24) :20907-20912 (2001).
Krogh, et al., “Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5′-bridging phosphorothiolates,” Virology 264(2) :441-51 (1999).
Liu, et al., “Mapping the 5′ and 3′ ends of tetrahymena thermophila mRNAs using ligase mediated amplification of cDNA ends (RLM-RACE),” Nucleic Acids Res. 21(21) :4954-4960 (1993).
Lockard, et al., “Labeling of eukaryotic messenger RNA 5′ terminus with phosphorus-32: Use of tobacco acid pyrophosphatase for removal of cap structure,” Gene Amp. Anal. 2:229-251 (1981).
Maruyama, et al., “Oligo-Capping: A simple method to replace the cap structure of eukaryotic mRNAs with oligonucleotides,” Gene 138:171-174 (1994).
Matthews, et al., “Analytical strategies for the use of DNA probes,” Anal. Biochem. 169:1-25 (1988).
Morham and Shuman, “Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I,” J. Biol. Chem. 267:15984-15992 (1992).
Morham and Shuman, “Phenotypic selection and characterization of mutant alleles of a eukaryotic DNA topoisomerase I,” Genes. Dev. 4(4) :515-24 (1990).
Palaniyar, et al., “SFV topoisomerase: sequence specificity in a genetically mapped interval,” Virology 221:351-354 (1996).
Petersen and Shuman, “DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate,” Nucleic Acids Res. 25(11) :2091-7 (1997).
Petersen and Shuman, “Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes,” J. Biol. Chem. 272(7) :3891-6 (1997).
Petersen, et al., “Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus,” Virology 230(2) :197-206 (1997).
Petersen, et al., “Mutations within a conserved region of vacc
Cooper & Dunham LLP
Sloan-Kettering Institute for Cancer Research
Vogel Nancy
White John P.
LandOfFree
Method for molecular cloning and polynucleotide synthesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for molecular cloning and polynucleotide synthesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for molecular cloning and polynucleotide synthesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104368